

CITATION REPORT

List of articles citing

On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease

DOI: 10.3389/fneur.2018.00455
Frontiers in Neurology, 2018, 9, 455.

Source: <https://exaly.com/paper-pdf/71377213/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
213	Wnt/ECatenin Signaling Pathway Governs a Full Program for Dopaminergic Neuron Survival, Neurorescue and Regeneration in the MPTP Mouse Model of Parkinson's Disease. 2018 , 19,		40
212	The locus coeruleus: Another vulnerability target in Parkinson's disease. 2019 , 34, 1423-1429		12
211	Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. 2019 , 142, 2558-2571		109
210	Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts. 2019 , 28, 3232-3243		30
209	L-DOPA causes mitochondrial dysfunction in vitro: A novel mechanism of L-DOPA toxicity uncovered. 2019 , 117, 105624		5
208	Cav2.3 channels contribute to dopaminergic neuron loss in a model of Parkinson's disease. 2019 , 10, 5094		31
207	Critical Role of Oxidatively Damaged DNA in Selective Noradrenergic Vulnerability. 2019 , 422, 184-201		2
206	Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?. 2019 , 34, 1406-1422		37
205	Alterations in Blood Monocyte Functions in Parkinson's Disease. 2019 , 34, 1711-1721		33
204	Increased vulnerability of nigral dopamine neurons after expansion of their axonal arborization size through D2 dopamine receptor conditional knockout. 2019 , 15, e1008352		30
203	Modelling transport and mean age of dense core vesicles in large axonal arbours. 2019 , 475, 20190284		3
202	Loss of SATB1 Induces p21-Dependent Cellular Senescence in Post-mitotic Dopaminergic Neurons. 2019 , 25, 514-530.e8		44
201	Unraveling Novel Mechanisms of Neurodegeneration Through a Large-Scale Forward Genetic Screen in. 2018 , 9, 700		20
200	Parkinson disease, substantia nigra vulnerability, and calbindin expression: Enlightening the darkness?. 2019 , 34, 161-163		4
199	Recalibrating the Relevance of Adult Neurogenesis. 2019 , 42, 164-178		101
198	Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders. 2019 , 126, 933-995		15
197	Lipostatic Mechanisms Preserving Cerebellar Lipids in MPTP-Treated Mice: Focus on Membrane Microdomains and Lipid-Related Gene Expression. 2019 , 12, 93		2

196	Dopaminergic Vulnerability in Parkinson Disease: The Cost of Humans' Habitual Performance. 2019 , 42, 375-383		13
195	A Computational Model of Loss of Dopaminergic Cells in Parkinson's Disease Due to Glutamate-Induced Excitotoxicity. 2019 , 13, 11		20
194	Role of MicroRNAs in Parkinson's Disease. 2019 , 20,		73
193	Brain MRI Reveals Ascending Atrophy in Parkinson's Disease Across Severity. <i>Frontiers in Neurology</i> , 2019 , 10, 1329	4.1	5
192	NCS-1 Deficiency Affects mRNA Levels of Genes Involved in Regulation of ATP Synthesis and Mitochondrial Stress in Highly Vulnerable Dopaminergic Neurons. 2019 , 12, 252		8
191	The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease. 2019 , 59, 263-289		41
190	Dopamin, oxidativer Stress und Protein-Chinonmodifikationen bei Parkinson und anderen neurodegenerativen Erkrankungen. 2019 , 131, 6580-6596		5
189	Dopamine, Oxidative Stress and Protein-Quinone Modifications in Parkinson's and Other Neurodegenerative Diseases. 2019 , 58, 6512-6527		87
188	Noradrenergic pathways of locus coeruleus in Parkinson's and Alzheimer's pathology. 2020 , 130, 251-261		1
187	Parkinson's Disease-Associated Changes in the Expression of Neurotrophic Factors and their Receptors upon Neuronal Differentiation of Human Induced Pluripotent Stem Cells. 2020 , 70, 514-521		2
186	Loss of fragile X mental retardation protein precedes Lewy pathology in Parkinson's disease. 2020 , 139, 319-345		9
185	Patient-Derived Midbrain Organoids to Explore the Molecular Basis of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020 , 11, 1005	4.1	10
184	Carnosine suppresses neuronal cell death and inflammation induced by 6-hydroxydopamine in an in vitro model of Parkinson's disease. 2020 , 15, e0240448		13
183	Mitochondrial biogenesis in organismal senescence and neurodegeneration. 2020 , 191, 111345		4
182	Determinants of seeding and spreading of β synuclein pathology in the brain. 2020 , 6,		25
181	The contribution of neurogenetics to understanding neurodegenerative diseases. 2020 , 34, 527-548		8
180	Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases?. 2020 , 14, 250		7
179	A Critical LRRK at the Synapse? The Neurobiological Function and Pathophysiological Dysfunction of LRRK2. 2020 , 13, 153		8

178	Calcium, Bioenergetics, and Parkinson's Disease. 2020 , 9,	23
177	Motor Coordination Disorders Evaluated through the Grid Test and Changes in the Nigral mRNA Expression in Rats with Pedunclopontine Lesion. 2020 , 10,	
176	Toxicity of Necrostatin-1 in Parkinson's Disease Models. 2020 , 9,	4
175	The Impact of Mitochondrial Dysfunction on Dopaminergic Neurons in the Olfactory Bulb and Odor Detection. 2020 , 57, 3646-3657	6
174	The Evolution-Driven Signature of Parkinson's Disease. 2020 , 43, 475-492	8
173	Neuron-autonomous susceptibility to induced synuclein aggregation is exacerbated by endogenous mutations and ameliorated by genetic knock-out. 2020 , 2, fcz052	8
172	Translation Imaging in Parkinson's Disease: Focus on Neuroinflammation. 2020 , 12, 152	18
171	Initiation and propagation of β synuclein aggregation in the nervous system. 2020 , 15, 19	80
170	Demonstration of brain region-specific neuronal vulnerability in human iPSC-based model of familial Parkinson's disease. 2020 , 29, 1180-1191	12
169	PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson's disease. 2020 , 15, 20	111
168	Glia-Derived Extracellular Vesicles in Parkinson's Disease. 2020 , 9,	14
167	Parkinson's disease: etiopathogenesis and treatment. 2020 , 91, 795-808	120
166	Elevated COUP-TFII expression in dopaminergic neurons accelerates the progression of Parkinson's disease through mitochondrial dysfunction. 2020 , 16, e1008868	7
165	Does Developmental Variability in the Number of Midbrain Dopamine Neurons Affect Individual Risk for Sporadic Parkinson's Disease?. 2020 , 10, 405-411	10
164	Polymorphic β synuclein Strains Modified by Dopamine and Docosahexaenoic Acid Interact Differentially with Tau Protein. 2020 , 57, 2741-2765	12
163	Selective neuronal vulnerability in Parkinson's disease. 2020 , 252, 61-89	12
162	Physical exercise protects against mitochondria alterations in the 6-hydroxydopamine rat model of Parkinson's disease. 2020 , 387, 112607	11
161	Boosting Antioxidant Self-defenses by Grafting Astrocytes Rejuvenates the Aged Microenvironment and Mitigates Nigrostriatal Toxicity in Parkinsonian Brain an Prosurvival Axis. 2020 , 12, 24	11

160	Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines. 2020 , 21,	69
159	Dynamic sleep stage transition process analysis in patients with Parkinson's disease having sleep apnea syndrome. 2021 , 25, 100656	0
158	Multitasking guardian of mitochondrial quality: Parkin function and Parkinson's disease. 2021 , 10, 5	13
157	Dying-back of ascending noradrenergic projections in Parkinson's disease. 2021 , 144, 2562-2564	
156	Adeno-Associated Virus Expression of β Synuclein as a Tool to Model Parkinson's Disease: Current Understanding and Knowledge Gaps. 2021 , 12, 1120-1137	1
155	The impact of dextran sodium sulphate and probiotic pre-treatment in a murine model of Parkinson's disease. 2021 , 18, 20	9
154	Influence of energy deficiency on the subcellular processes of Substantia Nigra Pars Compacta cell for understanding Parkinsonian neurodegeneration. 2021 , 11, 1754	7
153	Extracellular Vesicles in Premature Aging and Diseases in Adulthood Due to Developmental Exposures. 2021 , 12, 1516-1535	2
152	Inhibition of Orexin/Hypocretin Neurons Ameliorates Elevated Physical Activity and Energy Expenditure in the A53T Mouse Model of Parkinson's Disease. 2021 , 22,	6
151	Single-Cell Technologies in Parkinson's Disease. 2021 , 15-30	
150	Alternative splicing of auxiliary α -subunits stabilizes Cav2.3 Ca ²⁺ channel activity in continuously active midbrain dopamine neurons.	
149	REST Protects Dopaminergic Neurons from Mitochondrial and β Synuclein Oligomer Pathology in an Alpha Synuclein Overexpressing BAC-Transgenic Mouse Model. 2021 , 41, 3731-3746	6
148	Multi-Electrode Array Analysis Identifies Complex Dopamine Responses and Glucose Sensing Properties of Substantia Nigra Neurons in Mouse Brain Slices. 2021 , 13, 635050	3
147	Nicotinamide riboside alleviates Parkinson's disease symptoms but downregulates dopamine metabolism upon lactacystin-induced proteostasis failure.	
146	Therapeutic Applications of Botulinum Neurotoxin for Autonomic Symptoms in Parkinson's Disease: An Updated Review. 2021 , 13,	1
145	Fermented Soy Products: Beneficial Potential in Neurodegenerative Diseases. 2021 , 10,	20
144	Molecular Mechanisms Underlying Synaptic and Axon Degeneration in Parkinson's Disease. 2021 , 15, 626128	6
143	LRRK2 at the Crossroad of Aging and Parkinson's Disease. 2021 , 12,	3

142	Is there a Neurobiological Rationale for the Utility of the Iowa Gambling Task in Parkinson's Disease?. 2021 , 11, 405-419	2
141	The association of enteric neuropathy with gut phenotypes in acute and progressive models of Parkinson's disease. 2021 , 11, 7934	2
140	The β Synuclein Origin and Connectome Model (SOC Model) of Parkinson's Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline. 2021 , 11, 455-474	16
139	A Phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson's disease (PASADENA): rationale, design and baseline data.	3
138	Vesicular glutamate transporter modulates sex differences in dopamine neuron vulnerability to age-related neurodegeneration. 2021 , 20, e13365	2
137	Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease. 2021 , 36, 2085-2093	6
136	Prodromal Parkinson disease subtypes - key to understanding heterogeneity. 2021 , 17, 349-361	43
135	Can the lack of fibrillar form of alpha-synuclein in Lewy bodies be explained by its catalytic activity?.	
134	Increased LRRK2 kinase activity alters neuronal autophagy by disrupting the axonal transport of autophagosomes. 2021 , 31, 2140-2154.e6	29
133	Whether short peptides are good candidates for future neuroprotective therapeutics?. 2021 , 140, 170528	4
132	Bbc3 Loss Enhances Survival and Protein Clearance in Neurons Exposed to the Organophosphate Pesticide Chlorpyrifos. 2021 , 183, 378-392	1
131	Beyond Just Connectivity - Neuronal Activity Drives β Synuclein Pathology. 2021 , 36, 1487-1488	1
130	Alpha-Synuclein as a Biomarker of Parkinson's Disease: Good, but Not Good Enough. 2021 , 13, 702639	12
129	The Human Hippocampus in Parkinson's Disease: An Integrative Stereological and Proteomic Study. 2021 , 11, 1345-1365	3
128	The Prion-Like Spreading of Alpha-Synuclein in Parkinson's Disease: Update on Models and Hypotheses. 2021 , 22,	10
127	ASL expression in ALDH1A1 neurons in the substantia nigra metabolically contributes to neurodegenerative phenotype. 2021 , 140, 1471-1485	0
126	Kv4.3 channel downregulation mediates chronic post-lesional pacemaker acceleration in surviving dopamine substantia nigra neurons.	1
125	The locus coeruleus shows a spatial pattern of structural disintegration in Parkinson's disease.	0

124	A Parkinson's disease patient displaying increased neuromelanin-sensitive areas in the substantia nigra after rehabilitation with tDCS: a case report. 2021 , 1-8	1
123	Is there a special relationship between complex I activity and nigral neuronal loss in Parkinson's disease? A critical reappraisal. 2021 , 1767, 147434	6
122	Reduced Dopamine Signaling Impacts Pyramidal Neuron Excitability in Mouse Motor Cortex. 2021 , 8,	1
121	Ginsenoside Rg3 exerts a neuroprotective effect in rotenone-induced Parkinson's disease mice via its anti-oxidative properties. 2021 , 909, 174413	5
120	Evaluation of the neuroprotective effect of rutin on Drosophila melanogaster about behavioral and biochemical aspects induced by mercury chloride (HgCl). 2021 , 249, 109119	1
119	Dopamine D1/D3 receptor density may correlate with parkinson disease clinical features. 2021 , 8, 224-237	5
118	Nrf2/Wnt resilience orchestrates rejuvenation of glia-neuron dialogue in Parkinson's disease. 2020 , 36, 101664	9
117	The Parkinson's disease-associated gene ITPKB protects against β -synuclein aggregation by regulating ER-to-mitochondria calcium release. 2021 , 118,	12
116	Parkinson Disease-Linked Parkin Mediates Redox Reactions That Lower Oxidative Stress In Mammalian Brain.	3
115	Parkinson's disease, aging and adult neurogenesis: Wnt/ β -catenin signalling as the key to unlock the mystery of endogenous brain repair. 2020 , 19, e13101	43
114	A compendious summary of Parkinson's disease patient-derived iPSCs in the first decade. 2019 , 7, 685	5
113	The Pathology of Parkinson's Disease and Potential Benefit of Dietary Polyphenols. 2020 , 25,	19
112	Impaired Formation and Expression of Goal-Directed and Habitual Control in Parkinson's Disease. 2021 , 13, 734807	0
111	Constitutive nuclear accumulation of endogenous alpha-synuclein in mice causes motor dysfunction and cortical atrophy, independent of protein aggregation.	
110	Neuronal Dot1l is a broad mitochondrial gene-repressor associated with human brain aging via H3K79 hypermethylation.	0
109	Biomaterial Strategies for Restorative Therapies in Parkinson's Disease. 2021 , 12, 4224-4235	2
108	Baicalein protects against MPP/MPTP-induced neurotoxicity by ameliorating oxidative stress in SH-SY5Y cells and mouse model of Parkinson's disease. 2021 , 87, 188-194	2
107	Loss of SATB1 Induces a p21 Dependent Cellular Senescence Phenotype in Dopaminergic Neurons.	1

106	Adult ADHD in Neurocognitive and Neurological Disorders. 2020 , 287-305		
105	Vagal motoneurons in Parkinson's disease. 2020 , 327-343		0
104	Reduced dopamine signaling impacts pyramidal neuron excitability in mouse motor cortex.		0
103	Locus coeruleus degeneration is associated with disorganized functional topology in Parkinson's disease. 2021 , 32, 102873		0
102	A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. <i>Frontiers in Neurology</i> , 2021 , 12, 705407	4-1	5
101	VGLUT modulates sex differences in dopamine neuron vulnerability to age-related neurodegeneration.		0
100	Four main therapeutic keys for Parkinson's disease: A mini review. 2019 , 22, 716-721		3
99	PINK1 deficiency impairs osteoblast differentiation through aberrant mitochondrial homeostasis. 2021 , 12, 589		2
98	Alpha-Synuclein and Cognitive Decline in Parkinson Disease. 2021 , 11,		3
97	Animal models of Parkinson's disease: a guide to selecting the optimal model for your research.. 2021 , 5, NS20210026		5
96	Effect of Docosahexaenoic Acid (DHA) at the Enteric Level in a Synucleinopathy Mouse Model.. 2021 , 13,		0
95	Sox6 expression distinguishes dorsally and ventrally biased dopamine neurons in the substantia nigra with distinctive properties and embryonic origins. 2021 , 37, 109975		3
94	Immune response during idiopathic Parkinson's disease: From humans to animal models. 2021 , 2, 261-301		0
93	Brain Surface Area Alterations Correlate With Gait Impairments in Parkinson's Disease.. 2022 , 14, 806026		0
92	Single-cell transcriptomics of human iPSC differentiation dynamics reveal a core molecular network of Parkinson's disease.. 2022 , 5, 49		1
91	Olfactory Bulb D/D Receptor Availability after Intrastratial Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson's Disease.. 2022 , 14,		1
90	How Lazy Reading and Semantic Sloppiness May Harm Progress in Synucleinopathy Research.. 2022 , 12,		1
89	Can the lack of fibrillar form of alpha-synuclein in Lewy bodies be explained by its catalytic activity?. 2021 , 108754		0

88	Carving the senescent phenotype by the chemical reactivity of catecholamines: An integrative review.. 2022 , 75, 101570	
87	Clinical and imaging evidence of brain-first and body-first Parkinson's disease.. 2022 , 164, 105626	6
86	Genetic lesions of the noradrenergic system trigger induction of oxidative stress and inflammation in the ventral midbrain.. 2022 , 105302	0
85	The potential utility of smell testing to screen for neurodegenerative disorders.. 2022 ,	
84	Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson's Disease.. 2022 ,	0
83	Parkinsons Disease-Like Neuropathology and Phenotype Following Induction of Oxidative Stress and Inflammation in the Brain. 2022 , 3, 105-110	
82	Constitutive nuclear accumulation of endogenous alpha-synuclein in mice causes motor impairment and cortical dysfunction, independent of protein aggregation.. 2022 ,	1
81	Enhanced firing of locus coeruleus neurons and SK channel dysfunction are conserved in distinct models of prodromal Parkinson's disease.. 2022 , 12, 3180	0
80	Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies.. 2022 , 36, 327	1
79	Single-cell transcriptomic atlas of the human substantia nigra in Parkinson's disease.	2
78	αSynuclein binding activity of the plant growth promoter asterubine.. 2022 , 128677	1
77	The roles of connectivity and neuronal phenotype in determining the pattern of αsynuclein pathology in Parkinson's disease.. 2022 , 168, 105687	1
76	Phenolic-rich extract of avocado Persea americana (var. Colinred) peel blunts paraquat/maneb-induced apoptosis through blocking phosphorylation of LRRK2 kinase in human nerve-like cells.. 2021 ,	0
75	Application of Graphene in Tissue Engineering of the Nervous System.. 2021 , 23,	2
74	Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?. 2021 ,	8
73	Mitochondrial Function and Parkinson's Disease: From the Perspective of the Electron Transport Chain.. 2021 , 14, 797833	6
72	On cell loss in Parkinson's disease, and the citations that followed.. 2022 , 8, 38	
71	Stereotaxic-assisted gene therapy in Alzheimer's and Parkinson's diseases: Therapeutic potentials and clinical frontiers.. 2022 ,	

70	Table_1.docx. 2019 ,	
69	Image_1.TIF. 2020 ,	
68	Table_1.DOCX. 2020 ,	
67	Table_2.DOCX. 2020 ,	
66	Table_3.DOCX. 2020 ,	
65	Data_Sheet_1.pdf. 2019 ,	
64	Study on the Neuroprotective, Radical-Scavenging and MAO-B Inhibiting Properties of New Benzimidazole Arylhydrazones as Potential Multi-Target Drugs for the Treatment of Parkinson Disease. 2022 , 11, 884	4
63	Extracellular Alpha-Synuclein: Mechanisms for Glial Cell Internalization and Activation. 2022 , 12, 655	0
62	MicroRNA Alteration, Application as Biomarkers, and Therapeutic Approaches in Neurodegenerative Diseases.. 2022 , 23,	2
61	Long-Term Evaluation of Intranigral Transplantation of Human iPSC-Derived Dopamine Neurons in a Parkinson Disease Mouse Model. 2022 , 11, 1596	2
60	Characterization of retinal function and structure in the MPTP murine model of Parkinson's disease.. 2022 , 12, 7610	0
59	Predicting longitudinal brain atrophy in Parkinson disease using a Susceptible-Infected-Removed agent-based model.	
58	A review of diagnostic imaging approaches to assessing Parkinson's disease. 2022 , 6, 100037	
57	Aging and Parkinson Disease: Pathological Insight on Model Mice. 2022 , 367-386	
56	Modelling Synuclein Aggregation and Neurodegeneration with Fibril Seeds in Primary Cultures of Mouse Dopaminergic Neurons. 2022 , 11, 1640	2
55	Parkinson Disease-Specific Autoantibodies against the Neuroprotective Co-Chaperone STIP1. 2022 , 11, 1649	
54	Novel insights into the role of circular RNAs in Parkinson disease: An emerging renaissance in the management of neurodegenerative diseases.	0
53	Dysregulated Gene Expression in Lymphoblasts from Parkinson Disease. 2022 , 10, 20	0

52	Detailed insight into the pathophysiology and the behavioral complications associated with the Parkinson's disease and its medications. 2022 , 8,	
51	DAT and TH expression marks human Parkinson's disease in peripheral immune cells. 2022 , 8,	0
50	The role of NURR1 in metabolic abnormalities of Parkinson's disease. 2022 , 17,	1
49	α -subunit alternative splicing stabilizes Cav2.3 Ca ²⁺ channel activity during continuous midbrain dopamine neuron-like activity. 11,	1
48	A Critical Analysis of Intestinal Enteric Neuron Loss and Constipation in Parkinson's Disease. 2022 , 1-21	0
47	Dendritic involvement in inhibition and disinhibition of vulnerable dopaminergic neurons in healthy and pathological conditions. 2022 , 172, 105815	0
46	Neuron cell count with deep learning in highly dense hippocampus images. 2022 , 208, 118090	0
45	Targeting Macroautophagy as a Therapeutic Opportunity to Treat Parkinson's Disease. 10,	0
44	Treatment of radiation-induced brain injury with bisdemethoxycurcumin. 2023 , 18, 416	
43	A genome-scale metabolic model of <i>Drosophila melanogaster</i> for integrative analysis of brain diseases.	
42	Investigating the contribution of cytoarchitecture to diffusion MRI measures in gray matter using histology. 1,	0
41	Imaging the Limbic System in Parkinson's Disease: A Review of Limbic Pathology and Clinical Symptoms. 2022 , 12, 1248	0
40	Amelioration of pathologic β -synuclein-induced Parkinson's disease by irisin. 2022 , 119,	3
39	Impact of Environmental Risk Factors on Mitochondrial Dysfunction, Neuroinflammation, Protein Misfolding, and Oxidative Stress in the Etiopathogenesis of Parkinson's Disease. 2022 , 23, 10808	2
38	Fenofibrate promotes neuroprotection in a model of rotenone-induced Parkinson's disease. Publish Ahead of Print,	0
37	Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease.	0
36	Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease.	0
35	Excessive Daytime Sleepiness in Parkinson's Disease. Volume 14, 1589-1609	1

- 34 Axonal domain structure as a putative identifier of neuron-specific vulnerability to oxidative stress in cultured neurons. *ENEURO*.0139-22.2022 ○
- 33 Regional heterogeneity in mitochondrial function underlies region specific vulnerability in human brain ageing: Implications for neurodegeneration. **2022**, ○
- 32 Mapping Cholinergic Synaptic Loss in Parkinson's Disease: An [¹⁸F]FEOBV PET Case-Control Study. **2022**, 1-14 ○
- 31 Selective neurodegeneration generated by intravenous β synuclein pre-formed fibril administration is not associated with endogenous β synuclein levels in the rat brain. ○
- 30 Calcium Channels and Selective Neuronal Vulnerability in Parkinson's Disease. **2022**, 575-598 ○
- 29 Disruption of Locus Coeruleus Related Functional Networks in Parkinson's Disease. ○
- 28 Potential application of heat shock proteins as therapeutic targets in Parkinson's disease. **2022**, 105453 ○
- 27 Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson's Disease. 1
- 26 Molecular heterogeneity in the substantia nigra: A roadmap for understanding PD motor pathophysiology. **2022**, 175, 105925 ○
- 25 Bilirubin Prevents the TH+ Dopaminergic Neuron Loss in a Parkinson's Disease Model by Acting on TNF- α **2022**, 23, 14276 ○
- 24 Review on the interactions between dopamine metabolites and β synuclein in causing Parkinson's disease. **2023**, 162, 105461 ○
- 23 Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease. **2023**, 176, 105965 ○
- 22 Relevance of biochemical deep phenotyping for a personalised approach to Parkinson's disease. **2022**, ○
- 21 Single-nucleus co-expression networks of dopaminergic neurons support iron accumulation as a plausible explanation to their vulnerability in Parkinson's disease. ○
- 20 Neuronal Dot1l Activity Acts as a Mitochondrial Gene-Repressor Associated with Human Brain Aging via H3K79 Hypermethylation. **2023**, 24, 1387 ○
- 19 Parkin coregulates glutathione metabolism in adult mammalian brain. **2023**, 11, ○
- 18 Striatal dopamine loss in early Parkinson's disease: systematic review and novel analysis of dopamine transporter imaging. ○
- 17 The Role of LRRK2 in Intracellular Organelle Dynamics. **2023**, 167998 ○

- 16 Developmental origins of Parkinson disease: Improving the rodent models. **2023**, 86, 101880
- 15 Grey matter volume loss in Parkinson disease psychosis and its relationship with serotonergic gene expression: A meta-analysis. **2023**, 147, 105081
- 14 The Role of α -Synuclein in the Regulation of Serotonin System: Physiological and Pathological Features. **2023**, 11, 541
- 13 α -Synuclein induces prodromal symptoms of Parkinson disease via activating TLR2/MyD88/NF- κ B pathway in Schwann cells of vagus nerve in a rat model. **2023**, 20,
- 12 Urine biomarkers discovery by metabolomics and machine learning for Parkinson's disease diagnoses. **2023**, 108230
- 11 Sphingolipids in neurodegenerative diseases. 17,
- 10 Editorial: Neuronal network dysfunction in neurodegenerative disorders. 17,
- 9 Metabolomic Footprint of Disrupted Energetics and Amino Acid Metabolism in Neurodegenerative Diseases: Perspectives for Early Diagnosis and Monitoring of Therapy. **2023**, 13, 369
- 8 Rate control deficits during pinch grip and ankle dorsiflexion in early-stage Parkinson disease. **2023**, 18, e0282203
- 7 Neurotrophin mimetics and tropomyosin kinase receptors: a futuristic pharmacological tool for Parkinson.
- 6 Insights into Neurodegeneration in Parkinson's Disease from Single-Cell and Spatial Genomics. **2023**, 38, 518-525
- 5 Behavioral, neural and ultrastructural alterations in a graded-dose 6-OHDA mouse model of early-stage Parkinson disease.
- 4 Modulating arousal to overcome gait impairments in Parkinson disease: how the noradrenergic system may act as a double-edged sword. **2023**, 12,
- 3 Genetic Evidence for Endolysosomal Dysfunction in Parkinson Disease: A Critical Overview. **2023**, 24, 6338
- 2 CSF and PET biomarkers for noradrenergic dysfunction in neurodegenerative diseases: a systematic review and meta-analysis.
- 1 Inflammatory hallmarks in 6-OHDA- and LPS-induced Parkinson's disease in rats. **2023**, 30, 100616